RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Calithera Biosciences Stock

Calithera Biosciences ROE 2024

Calithera Biosciences ROE

-1.04

Ticker

CALA

ISIN

US13089P1012

WKN

A12AQH

In 2024, Calithera Biosciences's return on equity (ROE) was -1.04, a -55.48% increase from the -2.34 ROE in the previous year.

Calithera Biosciences Aktienanalyse

What does Calithera Biosciences do?

Calithera Biosciences Inc is a biopharmaceutical company specializing in the development of novel drugs for the treatment of cancer and other diseases. The company was founded in 2010 in South San Francisco, California, and has since made significant progress. History Calithera was founded by a group of successful leaders in the biotech industry who brought their extensive experience and knowledge into the development of innovative therapies. The company began its operations with the aim of finding novel molecular targets and compounds that have the potential to specifically attack cancer cells. The first product developed by the company was CB-839, an inhibitor of the enzyme glutaminase. The drug has the potential to inhibit the growth of cancer cells by disrupting the metabolic process in the cancer cells. CB-839 is currently undergoing clinical trials for the treatment of various types of cancer. Business Model Calithera Biosciences aims to address unmet medical needs by developing innovative and novel approaches to cancer and other diseases. The company takes a systematic approach and utilizes advanced technologies and research findings to develop new therapies. It works closely with leading research institutions and pharmaceutical companies to identify and develop new targets and compounds. Calithera Biosciences follows a pipeline strategy, having multiple compounds in various stages of clinical development. The company focuses on developing drugs that have high efficacy and targeted effects on cancer cells. Various Divisions Calithera Biosciences focuses on the development of drugs for the treatment of cancer and other diseases. The company has focused on researching compounds that target various factors responsible for cancer growth. The main divisions of the company are: - Metabolism: Calithera Biosciences has focused on developing drugs that inhibit the metabolism of cancer cells. CB-839, the first drug developed by the company, is an inhibitor of the enzyme glutaminase, which is important for the metabolism of cancer cells. - Immunotherapy: Calithera Biosciences has also focused on developing drugs that stimulate the immune system to fight cancer cells. The company is working on the development of drugs targeting myeloid-derived suppressor cells, a type of immune cells present in tumors. Products Calithera Biosciences has several products in development that aim to specifically attack and inhibit cancer cells. The company's key products include: - CB-839: CB-839 is an inhibitor of the enzyme glutaminase, which is important for the metabolism of cancer cells. The drug is currently undergoing clinical trials for the treatment of various types of cancer. - CB-1158: CB-1158 is an inhibitor of arginase, an enzyme important for the metabolism of immune cells. The drug has the potential to inhibit the growth of cancer cells by strengthening the immune system. CB-1158 is currently undergoing clinical trials for the treatment of various types of cancer. Conclusion Calithera Biosciences is an innovative biopharmaceutical company with a strong focus on the development of novel drugs for the treatment of cancer and other diseases. The company has focused on researching compounds that have targeted effects on cancer cells and stimulate the immune system to fight cancer cells. With a variety of compounds in different stages of clinical development, it is well positioned to bring groundbreaking therapies to the market. Calithera Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Calithera Biosciences's Return on Equity (ROE)

Calithera Biosciences's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Calithera Biosciences's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Calithera Biosciences's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Calithera Biosciences’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Calithera Biosciences stock

What is the ROE (Return on Equity) of Calithera Biosciences this year?

The ROE of Calithera Biosciences this year is -1.04 undefined.

How has the Return on Equity (ROE) of Calithera Biosciences developed compared to the previous year?

The ROE of Calithera Biosciences has increased by -55.48% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Calithera Biosciences?

A high ROE indicates that Calithera Biosciences generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Calithera Biosciences?

A low ROE can indicate that Calithera Biosciences is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Calithera Biosciences affect the company?

A change in ROE (Return on Equity) of Calithera Biosciences can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Calithera Biosciences?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Calithera Biosciences?

Some factors that can influence Calithera Biosciences's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Calithera Biosciences pay?

Over the past 12 months, Calithera Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Calithera Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Calithera Biosciences?

The current dividend yield of Calithera Biosciences is .

When does Calithera Biosciences pay dividends?

Calithera Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Calithera Biosciences?

Calithera Biosciences paid dividends every year for the past 0 years.

What is the dividend of Calithera Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Calithera Biosciences located?

Calithera Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Calithera Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Calithera Biosciences from 9/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/17/2024.

When did Calithera Biosciences pay the last dividend?

The last dividend was paid out on 9/17/2024.

What was the dividend of Calithera Biosciences in the year 2023?

In the year 2023, Calithera Biosciences distributed 0 USD as dividends.

In which currency does Calithera Biosciences pay out the dividend?

The dividends of Calithera Biosciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Calithera Biosciences stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Calithera Biosciences

Our stock analysis for Calithera Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Calithera Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.